Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data

Geahča maid

• Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data
  Dahkki: Card, T, et al.
  Almmustuhtton: (2019)
• Post-marketing safety experience of vedolizumab in older patients with inflammatory bowel disease
  Dahkki: Travis, S, et al.
  Almmustuhtton: (2018)
• Post-marketing experience of vedolizumab: Pneumonia and other respiratory tract infections
  Dahkki: Bhayat, F, et al.
  Almmustuhtton: (2017)
• Post-marketing experience of vedolizumab in inflammatory bowel disease: analysis of pneumonia and other respiratory tract infections
  Dahkki: Bhayat, F, et al.
  Almmustuhtton: (2017)
• P500 Post-marketing safety experience of vedolizumab in patients receiving concomitant treatment with other biologics
  Dahkki: Cohen, R, et al.
  Almmustuhtton: (2019)